Tag: MACE
-
Understanding COP-INH: A New Marker for Post-PCI Risk in ACS Patients
Introduction Dual antiplatelet therapy (DAPT), pairing aspirin with a P2Y12 receptor antagonist, is a cornerstone after percutaneous coronary intervention (PCI) with drug-eluting stents. While effective at reducing stent thrombosis and major adverse cardiac events (MACE), patient responses to clopidogrel and aspirin vary. High residual platelet reactivity (HRPR) after clopidogrel treatment correlates with worse outcomes, underscoring…
-
COP-INH Score: A New Way to Predict Post-PCI Risks in ACS Patients
Understanding the Need for Better Post-PCI Risk Prediction Dual antiplatelet therapy (DAPT), typically aspirin plus a P2Y12 receptor antagonist, is standard after percutaneous coronary intervention (PCI) with drug-eluting stents. While this approach reduces stent thrombosis and major adverse cardiac events (MACE), individual responses to antiplatelet drugs vary widely. High residual platelet reactivity (HRPR) after clopidogrel…
-
COP-INH Score: A New Metric for Predicting Post-PCI Outcomes in ACS Patients
Understanding the Challenge: Platelet Reactivity After PCI Dual antiplatelet therapy (DAPT), typically aspirin plus a P2Y12 receptor antagonist, is standard care after percutaneous coronary intervention (PCI) with drug-eluting stents. While this regimen reduces stent thrombosis and major adverse cardiac events (MACE), patient responses vary. High residual platelet reactivity (HRPR) after clopidogrel therapy has been linked…
-
Does Serum Uric Acid Predict Cardiovascular Events in Older Adults? Insights from a Berlin Cohort
Overview: What the BIS study examined Recent findings from a population-based prospective cohort in Berlin raise important questions about serum uric acid (SUA) and its role in cardiovascular risk among older adults. Using data from the Berlin Initiative Study (BIS), researchers followed 2,058 community-dwelling seniors (average age about 80) to explore whether SUA levels predict…
-
Serum Uric Acid and the Risk of Major Adverse Cardiovascular Events and Death in Older Adults: Insights from a Berlin Population Study
Overview Understanding how serum uric acid (SUA) relates to cardiovascular outcomes in older adults is crucial given the high prevalence of hyperuricemia in this population. A population-based prospective analysis using the Berlin Initiative Study (BIS) cohort provides new insights. The study followed community-dwelling adults aged 70 and older to examine whether baseline and time-updated SUA…
-
Serum Uric Acid and Cardiovascular Risk in Older Adults: Insights from the Berlin Initiative Study
Background and purpose Serum uric acid (SUA) is a biomarker that has drawn attention for potential links to cardiovascular disease and mortality. A population-based prospective cohort study using data from the Berlin Initiative Study (BIS) examined whether SUA levels in community-dwelling older adults influence the risk of major adverse cardiovascular events (MACE) and death. The…